This is promising:
Drugmaker executives whose companies promote unauthorized uses of their medicines may be targeted by U.S. regulators for misdemeanor prosecutions, Food and Drug Administration Deputy Chief for Litigation Eric Blumberg said.
* * * *
‘“It’s clear we’re not getting the job done with large, monetary settlements,” Blumberg said. “Unless the government shows